Literature DB >> 11706742

Multiple endocrine neoplasia type 2 and the practice of molecular medicine.

C Eng1.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 11706742     DOI： 10.1023/a:1026514301172

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN： 1389-9155            Impact factor:   6.514


× No keyword cloud information.
  61 in total

1.  Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation.

Authors:  O Nilsson; L E Tisell; S Jansson; H Ahlman; O Gimm; C Eng
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

Review 2.  Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease.

Authors:  C Eng
Journal:  N Engl J Med       Date:  1996-09-26       Impact factor: 91.245

3.  Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine.

Authors:  I Schuffenecker; M Virally-Monod; R Brohet; D Goldgar; B Conte-Devolx; L Leclerc; O Chabre; A Boneu; J Caron; C Houdent; E Modigliani; V Rohmer; M Schlumberger; C Eng; P J Guillausseau; G M Lenoir
Journal:  J Clin Endocrinol Metab       Date:  1998-02       Impact factor: 5.958

4.  Germline mutation of RET codon 883 in two cases of de novo MEN 2B.

Authors:  D P Smith; C Houghton; B A Ponder
Journal:  Oncogene       Date:  1997-09-04       Impact factor: 9.867

5.  Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.

Authors: 
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

6.  Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.

Authors:  A Pasini; O Geneste; P Legrand; M Schlumberger; M Rossel; L Fournier; B B Rudkin; I Schuffenecker; G M Lenoir; M Billaud
Journal:  Oncogene       Date:  1997-07-24       Impact factor: 9.867

7.  Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.

Authors:  A M Moers; R M Landsvater; C Schaap; J M Jansen-Schillhorn van Veen; I A de Valk; G H Blijham; J W Höppener; T M Vroom; H K van Amstel; C J Lips
Journal:  Am J Med       Date:  1996-12       Impact factor: 4.965

8.  Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium.

Authors:  L M Mulligan; D J Marsh; B G Robinson; I Schuffenecker; J Zedenius; C J Lips; R F Gagel; S I Takai; W W Noll; M Fink
Journal:  J Intern Med       Date:  1995-10       Impact factor: 8.989

9.  Direct, non-radioactive detection of mutations in multiple endocrine neoplasia type 2A families.

Authors:  R McMahon; L M Mulligan; C S Healey; S J Payne; M Ponder; M A Ferguson-Smith; D E Barton; B A Ponder
Journal:  Hum Mol Genet       Date:  1994-04       Impact factor: 6.150

Review 10.  Medullary thyroid carcinoma in children.

Authors:  R L Telander; C R Moir
Journal:  Semin Pediatr Surg       Date:  1994-08       Impact factor: 2.754
View more
  1 in total

1.  The RET mutation E768D confers a late-onset familial medullary thyroid carcinoma -- only phenotype with incomplete penetrance: implications for screening and management of carrier status.

Authors:  Tabib Dabir; Steven J Hunter; Colin F J Russell; Damien McCall; Patrick J Morrison
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.